Closed Incision Negative Pressure Wound Therapy for the Prevention of Surgical Site Infections in Abdominal Surgery
Launched by INSEL GRUPPE AG, UNIVERSITY HOSPITAL BERN · Sep 28, 2023
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new way to help prevent surgical site infections (SSIs) after abdominal surgery using a method called closed incision negative pressure wound therapy (ciNPWT). SSIs are common complications that can make recovery harder and cost more for patients. ciNPWT uses a gentle vacuum to help keep the surgical incision clean and promote healing. The main goal of this study is to find out if using this therapy can reduce the risk of infections for patients who have had surgery on their abdomen.
To participate in this trial, individuals must be adults over 18 years old who are undergoing certain types of abdominal surgeries, such as elective or emergency laparotomies (a type of surgery where the abdomen is opened). The surgical incision must be at least 10 centimeters long and classified as clean or clean-contaminated. Patients with dirty or infected wounds, those under 18, or individuals with allergies to silver will not be eligible. Participants in the trial will undergo standard surgical procedures and, if selected, may receive the ciNPWT treatment to see how it affects their recovery. The trial is not yet recruiting, so there will be more information available as it begins.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Elective or emergency laparotomy, or laparoscopy converted to laparotomy, including surgery for complications after elective operations
- • Incision length ≥ 10 cm
- • Centers for Disease Control and Prevention (CDC) wound class 1 and 2 (clean, clean-contaminated)
- • Abdominal closure with or without mesh implantation
- • Primary abdominal closure or closure after open abdomen treatment
- • Age over 18 years
- • Written informed consent
- Exclusion Criteria:
- • Age ≤ 18 years
- • CDC wound class 4 (dirty/infected wound)
- • Organ transplantation
- • Sensitivity or allergy to silver
About Insel Gruppe Ag, University Hospital Bern
Insel Gruppe AG, the umbrella organization for the University Hospital Bern, is a leading healthcare provider in Switzerland, renowned for its commitment to advancing medical research and patient care. As a key player in clinical trials, Insel Gruppe AG integrates cutting-edge scientific inquiry with clinical excellence, facilitating innovative studies that span a wide range of medical disciplines. The institution prioritizes collaboration with academic partners and industry stakeholders to enhance the understanding of diseases and develop effective treatment options, ultimately aiming to improve patient outcomes and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bern, , Switzerland
Patients applied
Trial Officials
Tobias Haltmeier, MD
Principal Investigator
Inselspital, Bern University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported